These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 31473943)

  • 21. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
    Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.
    Levis M
    Future Oncol; 2014; 10(9):1571-9. PubMed ID: 25145428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.
    Moore AS; Faisal A; Mak GWY; Miraki-Moud F; Bavetsias V; Valenti M; Box G; Hallsworth A; de Haven Brandon A; Xavier CPR; Stronge R; Pearson ADJ; Blagg J; Raynaud FI; Chopra R; Eccles SA; Taussig DC; Linardopoulos S
    Blood Adv; 2020 Apr; 4(7):1478-1491. PubMed ID: 32282883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
    Swaminathan M; Kantarjian HM; Levis M; Guerra V; Borthakur G; Alvarado Y; DiNardo CD; Kadia T; Garcia-Manero G; Ohanian M; Daver N; Konopleva M; Pemmaraju N; Ferrajoli A; Andreeff M; Jain N; Estrov Z; Jabbour EJ; Wierda WG; Pierce S; Pinsoy MR; Xiao L; Ravandi F; Cortes JE
    Haematologica; 2021 Aug; 106(8):2121-2130. PubMed ID: 33853292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
    Sexauer A; Perl A; Yang X; Borowitz M; Gocke C; Rajkhowa T; Thiede C; Frattini M; Nybakken GE; Pratz K; Karp J; Smith BD; Levis M
    Blood; 2012 Nov; 120(20):4205-14. PubMed ID: 23012328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.
    Darici S; Jørgensen HG; Huang X; Serafin V; Antolini L; Barozzi P; Luppi M; Forghieri F; Marmiroli S; Zavatti M
    Adv Biol Regul; 2023 Aug; 89():100974. PubMed ID: 37245251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
    Wang P; Zhang Y; Xiang R; Yang J; Xu Y; Deng T; Zhou W; Wang C; Xiao X; Wang S
    Cancer Res; 2024 Mar; 84(6):905-918. PubMed ID: 38231480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib
    Dumas PY; Naudin C; Martin-Lannerée S; Izac B; Casetti L; Mansier O; Rousseau B; Artus A; Dufossée M; Giese A; Dubus P; Pigneux A; Praloran V; Bidet A; Villacreces A; Guitart A; Milpied N; Kosmider O; Vigon I; Desplat V; Dusanter-Fourt I; Pasquet JM
    Haematologica; 2019 Oct; 104(10):2017-2027. PubMed ID: 30923103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
    Marensi V; Keeshan KR; MacEwan DJ
    Biochem Pharmacol; 2021 Jan; 183():114348. PubMed ID: 33242449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia.
    He BL; Yang N; Man CH; Ng NK; Cher CY; Leung HC; Kan LL; Cheng BY; Lam SS; Wang ML; Zhang CX; Kwok H; Cheng G; Sharma R; Ma AC; So CW; Kwong YL; Leung AY
    EMBO Mol Med; 2020 Apr; 12(4):e10895. PubMed ID: 32134197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
    Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
    Cooper TM; Cassar J; Eckroth E; Malvar J; Sposto R; Gaynon P; Chang BH; Gore L; August K; Pollard JA; DuBois SG; Silverman LB; Oesterheld J; Gammon G; Magoon D; Annesley C; Brown PA
    Clin Cancer Res; 2016 Aug; 22(16):4014-22. PubMed ID: 26920889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
    Smith CC; Wang Q; Chin CS; Salerno S; Damon LE; Levis MJ; Perl AE; Travers KJ; Wang S; Hunt JP; Zarrinkar PP; Schadt EE; Kasarskis A; Kuriyan J; Shah NP
    Nature; 2012 Apr; 485(7397):260-3. PubMed ID: 22504184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Naqvi K; Ravandi F
    Leuk Lymphoma; 2019 Aug; 60(8):1866-1876. PubMed ID: 30997851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
    Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
    Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.
    Smith CC; Levis MJ; Frankfurt O; Pagel JM; Roboz GJ; Stone RM; Wang ES; Severson PL; West BL; Le MH; Kayser S; Lam B; Hsu HH; Zhang C; Bollag G; Perl AE
    Blood Adv; 2020 Apr; 4(8):1711-1721. PubMed ID: 32330242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in
    Dumas PY; Villacreces A; Guitart AV; El-Habhab A; Massara L; Mansier O; Bidet A; Martineau D; Fernandez S; Leguay T; Pigneux A; Vigon I; Pasquet JM; Desplat V
    Clin Cancer Res; 2021 Nov; 27(21):6012-6025. PubMed ID: 34400415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
    Tzogani K; Røshol H; Olsen HH; Aas IB; Dalhus ML; Håkonsen GD; Nilssen LS; Lindberg V; Økvist M; Bolstad B; Rogovska I; Karpova N; Enzmann H; Gisselbrecht C; Pignatti F
    Oncologist; 2020 Jul; 25(7):e1070-e1076. PubMed ID: 32154636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.